Clinical Trials Logo

Generalized Anxiety Disorder clinical trials

View clinical trials related to Generalized Anxiety Disorder.

Filter by:

NCT ID: NCT05967468 Recruiting - Clinical trials for Generalized Anxiety Disorder

Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder

Start date: September 14, 2023
Phase: N/A
Study type: Interventional

Anxiety and obsessive-compulsive disorders are among the most common in children. Although cognitive behavioral therapy (CBT) is an effective and evidence-based treatment for such disorders, access to CBT is often limited. Family-based and internet-delivered therapy is one method to increase access to care. The purpose of this project is to evaluate the comparative efficacy and treatment mechanisms of two lower-intensity but effective treatments for families of children with anxiety or obsessive compulsive disorder (OCD) via telehealth compared to an adapted Relaxation and Mentorship Training (RMT) intervention involving breathing exercises with a therapist.

NCT ID: NCT05906849 Recruiting - Clinical trials for Generalized Anxiety Disorder

Where We All Meet: ACT Approach to Adolescents Anxiety Disorders

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Transdiagnostic approaches have been proposed as more truthfully representing mental health problems. Acceptance and Commitment Therapy (ACT) is a transdiagnostic approach that proposes Psychological Inflexibility/Flexibility (PI/PF) as the root of human suffering/flourishing. ACT has been recognized as conceptually and clinically relevant for adult disorders. However, during adolescence, when anxiety disorders are highly prevalent, the same evidence is scarce. Specifically, methodologically robust designs investigating ACT's efficacy on adolescents' ADs are scarce and mechanisms underlying change during ACT for adolescents with ADs have not been investigated. Therefore, this study aims to adapt, implement, and investigate the efficacy of an online delivered (through videoconference) ACT intervention to adolescents presenting SAD or GAD, thus contributing to amplifying the transdiagnostic application of ACT to these disorders. A Randomized Controlled Trial (RCT) with 3 groups (i.e., Control, GAD intervention, and SAD intervention groups) of adolescents aged between 14 and 18 years old will be conducted. Outcome measurement will be assessed at pre-intervention, post-intervention, and at 3- and 6-month follow-ups. The investigators expect improvements in outcome variables (e.g., anxiety symptoms) at post-treatment for intervention groups. When comparing changes in outcome variables between the control and the intervention groups, improvements are expected only in the groups receiving intervention. Additionally, similar effects on outcome measures are expected in both intervention groups with gains being maintained over time (i.e., at 3- and 6-months follow-up). Finally, changes in PI/PF processes are expected to predict changes in outcome variables in both intervention groups. This RCT will provide valuable insights that can potentially enhance the efficacy of treatment modalities, contributing to improved well-being for adolescents with ADs.

NCT ID: NCT05895721 Recruiting - Clinical trials for Generalized Anxiety Disorder

Virtual Reality for Generalized Anxiety Disorders

VR-GAD
Start date: February 21, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to apply Virtual Reality as an adjunct treatment for Generalized Anxiety Disorder. The main question it aims to answer are: - Determination of the efficacy of VR modules as an adjunct therapy in improving GAD-7 scores - Assessment of the acceptability of VR modules as an adjunct therapy to the standard of care Participants will randomized into two arms: - Control Arm: Standard of Care only - Intervention Arm: Standard of Care + VR Modules

NCT ID: NCT05849493 Recruiting - Clinical trials for Generalized Anxiety Disorder

Effects and Mechanisms of Change of Internet Delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder

ORIGAMI
Start date: May 19, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare two psychological treatments for Generalized Anxiety Disorder. The main questions it aims to answer are: How well do these treatments work compared to earlier studies? Is one of the treatments more effective than the other? Are the treatments working the way that we think they do? Specifically, do changes in the variables that these treatments aim to target predict changes in anxiety symptoms? Participants will be randomized to two different internet-based cognitive behavioral therapy (ICBT) programs: Intolerance of uncertainty-based ICBT and metacognition-based ICBT. Both programs consist of 8 treatment modules and run for 10 weeks. A psychologist will respond to the participants assignments and exercises and will respond to messages.

NCT ID: NCT05800925 Recruiting - Clinical trials for Major Depressive Disorder

Triage Survey for Psychiatry Research Eligibility

TRIAGE-Psych
Start date: December 21, 2021
Phase:
Study type: Observational

TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

NCT ID: NCT05749055 Recruiting - Clinical trials for Generalized Anxiety Disorder

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

ENCALM
Start date: July 3, 2023
Phase: Phase 2
Study type: Interventional

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

NCT ID: NCT05729373 Recruiting - Clinical trials for Generalized Anxiety Disorder

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Start date: March 8, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.

NCT ID: NCT05717439 Recruiting - Clinical trials for Major Depressive Disorder

Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults With PTSD

Start date: March 1, 2023
Phase:
Study type: Observational

The aim of this study is to obtain data on the feasibility of the Senseye Diagnostic Tool (DT) to assess the presence and severity of post-traumatic stress disorder (PTSD) symptoms. The study will also collect data on Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) to aid in assessing the presence and severity of these disorders both for the purpose of discerning them from PTSD and determining the feasibility of diagnosing them independently.

NCT ID: NCT05671419 Recruiting - Clinical trials for Major Depressive Disorder

Mindful Self-Compassion for Anxiety Disorders and Depression

Start date: January 16, 2022
Phase: N/A
Study type: Interventional

The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder.

NCT ID: NCT05574140 Recruiting - Clinical trials for Generalized Anxiety Disorder

BreathinG-induced Myocardial and Cerebral Perfusion in Anxiety Disorders

B-GLAD
Start date: July 15, 2022
Phase:
Study type: Observational

This study aims to view variations in MRI measurements of the heart and the brain in people with anxiety versus healthy volunteers. The MRI measurements used will be Oxygenation-Sensitive Cardiac MRI (OS-CMR), a recent type of MRI which is safe, fast, and non-invasive.